Biohaven (BHVN) director trust purchase corrected to 28,400 shares

Q: Why was the Biohaven (BHVN) Form 4/A filing by John W. Childs amended?

The Form 4/A was filed to correct the nature of indirect ownership . It clarifies that all 28,400 acquired shares were held by the John W Childs 2013 Revocable Trust , and that no shares from this transaction were acquired through the 2013 Charitable Remainder Trust.

Q: What price range did the Biohaven (BHVN) insider purchase by John W. Childs cover?

The reported weighted average purchase price was $30.4266 per share. Footnotes state that the 28,400 Biohaven common shares were bought in multiple transactions at prices ranging from $30.17 to $30.89 , with full trade details available on request from the reporting person.

Q: Did the 2013 Charitable Remainder Trust acquire Biohaven (BHVN) shares in this amended Form 4/A?

According to the amendment, no Biohaven common shares were acquired through the 2013 Charitable Remainder Trust in this transaction. The earlier form had misallocated part of the purchase to that trust, which this Form 4/A corrects fully.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.

The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.

Insider Trade Summary

Net Buyer: 28,400 shares ($864,115)

Net Buy 2 txns

Insider CHILDS JOHN W

Role Director

Bought 28,400 shs ($864K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	28,400	$30.4266	$864K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 2,323,971 shares (Indirect, By John W Childs 2013 Revocable Trust)

Footnotes (1)

This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on March 5, 2025 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 3,400 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and 25,000 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 28,400 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust, and no Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

03/09/2026 - 06:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHILDS JOHN W

(Last)

(First)

(Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN

06510

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/05/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	03/04/2025		P		28,400⁽¹⁾	A	$30.4266⁽²⁾	2,323,971⁽²⁾	I	By John W Childs 2013 Revocable Trust
Common Shares								73,170⁽²⁾	I	By 2013 Charitable Remainder Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on March 5, 2025 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 3,400 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and 25,000 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 28,400 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust, and no Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

Remarks:

	/s/ George Clark, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did John W. Childs report for Biohaven (BHVN)?

John W. Childs reported an indirect open-market purchase of 28,400 Biohaven common shares through the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share, according to the amended Form 4/A filing details.

Why was the Biohaven (BHVN) Form 4/A filing by John W. Childs amended?

The Form 4/A was filed to correct the nature of indirect ownership. It clarifies that all 28,400 acquired shares were held by the John W Childs 2013 Revocable Trust, and that no shares from this transaction were acquired through the 2013 Charitable Remainder Trust.

What price range did the Biohaven (BHVN) insider purchase by John W. Childs cover?

The reported weighted average purchase price was $30.4266 per share. Footnotes state that the 28,400 Biohaven common shares were bought in multiple transactions at prices ranging from $30.17 to $30.89, with full trade details available on request from the reporting person.

How are the Biohaven (BHVN) shares from the transaction held by John W. Childs?

The 28,400 Biohaven common shares from this transaction are held indirectly through the John W Childs 2013 Revocable Trust. The amended filing specifies this trust as the sole vehicle for these acquired shares, rather than the previously referenced charitable remainder trust.

Did the 2013 Charitable Remainder Trust acquire Biohaven (BHVN) shares in this amended Form 4/A?

According to the amendment, no Biohaven common shares were acquired through the 2013 Charitable Remainder Trust in this transaction. The earlier form had misallocated part of the purchase to that trust, which this Form 4/A corrects fully.